STAGE IIC PROSTATE CANCER AJCC V8
Clinical trials for STAGE IIC PROSTATE CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IIC PROSTATE CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IIC PROSTATE CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a targeted drug boost prostate cancer treatment?
Disease control Recruiting nowThis study tests whether adding the drug niraparib to standard hormone therapy after radiation helps control high-risk prostate cancer that hasn't spread far. About 200 men will receive either hormone therapy alone or hormone therapy plus niraparib. The goal is to see if the comb…
Matched conditions: STAGE IIC PROSTATE CANCER AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 18, 2026 11:50 UTC
-
New radiation approach may offer shorter, safer treatment for recurrent prostate cancer
Disease control Recruiting nowThis study tests whether a precise, short-course radiation method (SBRT) works as well as a slightly longer radiation approach (hypofractionated radiotherapy) for men whose prostate cancer has come back or spread to a few spots after surgery. About 118 participants will receive o…
Matched conditions: STAGE IIC PROSTATE CANCER AJCC V8
Phase: PHASE3 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 18, 2026 11:48 UTC
-
Hormone boost may sharpen prostate cancer scans
Diagnosis Recruiting nowThis study tests whether a short course of hormone therapy (relugolix) can make PSMA PET/CT scans better at finding prostate cancer that has spread to lymph nodes. About 30 men with high-risk prostate cancer will get the hormone drug for 5, 10, or 15 days before their scan. The g…
Matched conditions: STAGE IIC PROSTATE CANCER AJCC V8
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Diagnosis
Last updated Jun 15, 2026 19:02 UTC
-
Heart showdown: which prostate cancer drug is kinder to your heart?
Knowledge-focused Recruiting nowThis study compares two hormone-lowering drugs, Orgovyx and Eligard, in men with prostate cancer who are also getting radiation therapy. The goal is to see which drug has less impact on heart function and overall heart health. About 70 participants will undergo heart tests, exerc…
Matched conditions: STAGE IIC PROSTATE CANCER AJCC V8
Phase: PHASE2 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Jun 18, 2026 11:53 UTC